Nuveen LLC Takes $1.76 Million Position in 10x Genomics $TXG

Key Points

• Nuveen LLC has acquired a new position in 10x Genomics, purchasing approximately 201,061 shares valued at around <$1.76 million, representing 0.16% ownership.
• Multiple institutional investors, including Invesco Ltd. and Charles Schwab, have increased their holdings in 10x Genomics during the first quarter, highlighting growing interest in the company.
• Despite positive quarterly earnings reports, analysts have mixed views with target price adjustments ranging from $12.00 to $18.00, resulting in an average rating of "Hold" with a price target of $13.54.

Nuveen LLC acquired a new stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 201,061 shares of the company's stock, valued at approximately $1,755,000. Nuveen LLC owned about 0.16% of 10x Genomics as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in TXG. GAMMA Investing LLC raised its position in 10x Genomics by 81.8% in the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after purchasing an additional 1,614 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $32,000. Signaturefd LLC grew its stake in shares of 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock valued at $37,000 after purchasing an additional 2,409 shares during the last quarter. Whittier Trust Co. bought a new position in 10x Genomics in the first quarter valued at approximately $41,000. Finally, PNC Financial Services Group Inc. boosted its stake in 10x Genomics by 153.6% in the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock valued at $45,000 after acquiring an additional 3,119 shares during the last quarter. Institutional investors and hedge funds own 84.68% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TXG shares. The Goldman Sachs Group reduced their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating on the stock in a research note on Monday, May 12th. Morgan Stanley reduced their price objective on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating on the stock in a research note on Tuesday, August 12th. JPMorgan Chase & Co. reduced their price objective on shares of 10x Genomics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research note on Friday, May 9th. UBS Group lifted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Bank of America lifted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the stock a "neutral" rating in a research report on Thursday, June 26th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $13.54.

Insider Buying and Selling

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the sale, the chief executive officer owned 945,892 shares of the company's stock, valued at $13,043,850.68. The trade was a 0.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $307,723.85. Following the completion of the sale, the chief financial officer directly owned 309,273 shares of the company's stock, valued at $4,264,874.67. This represents a 6.73% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,149 shares of company stock valued at $539,865. Company insiders own 10.03% of the company's stock.

10x Genomics Trading Down 1.9%

Shares of 10x Genomics stock traded down $0.27 during trading on Monday, hitting $14.01. 1,566,109 shares of the stock were exchanged, compared to its average volume of 3,022,419. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -20.01 and a beta of 2.00. The company has a fifty day moving average price of $12.98 and a 200-day moving average price of $10.70. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. 10x Genomics's revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Equities research analysts forecast that 10x Genomics will post -1.43 EPS for the current fiscal year.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.